HUE043524T2 - DGATl inhibitort tartalmazó gyógyászati készítmény - Google Patents
DGATl inhibitort tartalmazó gyógyászati készítményInfo
- Publication number
- HUE043524T2 HUE043524T2 HUE11779278A HUE11779278A HUE043524T2 HU E043524 T2 HUE043524 T2 HU E043524T2 HU E11779278 A HUE11779278 A HU E11779278A HU E11779278 A HUE11779278 A HU E11779278A HU E043524 T2 HUE043524 T2 HU E043524T2
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- dgat1 inhibitor
- dgat1
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39310310P | 2010-10-14 | 2010-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE043524T2 true HUE043524T2 (hu) | 2019-08-28 |
Family
ID=44908106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE11779278A HUE043524T2 (hu) | 2010-10-14 | 2011-10-14 | DGATl inhibitort tartalmazó gyógyászati készítmény |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20130190354A1 (hu) |
| EP (1) | EP2627319B1 (hu) |
| JP (1) | JP6060081B2 (hu) |
| KR (1) | KR20130100311A (hu) |
| CN (1) | CN103179957B (hu) |
| AR (1) | AR083417A1 (hu) |
| AU (1) | AU2011316003B2 (hu) |
| BR (1) | BR112013008757A2 (hu) |
| CA (1) | CA2813781C (hu) |
| CL (1) | CL2013001001A1 (hu) |
| CO (1) | CO6710915A2 (hu) |
| DK (1) | DK2627319T3 (hu) |
| EC (1) | ECSP13012755A (hu) |
| ES (1) | ES2712064T3 (hu) |
| GT (1) | GT201300096A (hu) |
| HU (1) | HUE043524T2 (hu) |
| IL (1) | IL225434A0 (hu) |
| MA (1) | MA34599B1 (hu) |
| MX (1) | MX2013004162A (hu) |
| NZ (1) | NZ608558A (hu) |
| PE (1) | PE20140375A1 (hu) |
| PL (1) | PL2627319T3 (hu) |
| PT (1) | PT2627319T (hu) |
| RU (1) | RU2595866C2 (hu) |
| SG (1) | SG189078A1 (hu) |
| SI (1) | SI2627319T1 (hu) |
| TR (1) | TR201902435T4 (hu) |
| WO (1) | WO2012051488A1 (hu) |
| ZA (1) | ZA201302108B (hu) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013163508A1 (en) * | 2012-04-27 | 2013-10-31 | Novartis Ag | Tetrahydropyran dgat1 inhibitors |
| WO2013169648A1 (en) * | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| CN107530307A (zh) | 2015-03-13 | 2018-01-02 | 艾斯柏伦治疗公司 | 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法 |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| TWI711464B (zh) * | 2015-11-19 | 2020-12-01 | 欣耀生醫股份有限公司 | 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR20240014585A (ko) | 2016-03-04 | 2024-02-01 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
| US10632092B2 (en) | 2017-08-30 | 2020-04-28 | First Fruits Business Ministry, Llc | Composition for and method to increase serum adiponectin and reduce body fat |
| EA202092190A1 (ru) * | 2018-03-16 | 2020-11-19 | Анджи Фармасьютикалз Инк. | Композиции и способы для лечения сильного запора |
| US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997017951A1 (en) | 1995-11-14 | 1997-05-22 | Knoll Pharmaceutical Company | Stabilized thyroid hormone preparations and methods of making same |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| DE19816070A1 (de) * | 1998-04-09 | 1999-10-14 | Aventis Res & Tech Gmbh & Co | Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden |
| BR0215193A (pt) * | 2001-12-21 | 2004-11-16 | Pfizer Prod Inc | Formulações de azitromicina diretamente compressìveis |
| MX2007013049A (es) * | 2005-04-19 | 2008-01-11 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad. |
| KR101219042B1 (ko) * | 2005-12-06 | 2013-01-07 | 삼성디스플레이 주식회사 | 반투과형 액정 표시 장치 |
| JP5165582B2 (ja) * | 2005-12-16 | 2013-03-21 | メルク・シャープ・エンド・ドーム・コーポレイション | ジペプチジルペプチダーゼ−４インヒビターとメトホルミンとを組み合わせた医薬組成物 |
| US20070208067A1 (en) | 2006-03-06 | 2007-09-06 | Wyeth | Tablet Formulations and Processes |
| US20070224258A1 (en) | 2006-03-22 | 2007-09-27 | Bunick Frank J | Dosage forms having a randomized coating |
| CA2647819C (en) * | 2006-03-31 | 2012-12-11 | Novartis Ag | Phenylcyclohexyl derivatives as dgat1 inhibitors |
| ES2421326T3 (es) | 2006-11-29 | 2013-08-30 | Abbvie Inc. | Inhibidores de la enzima diacilglicerol O-aciltransferasa de tipo 1 |
| US20080145425A1 (en) * | 2006-12-15 | 2008-06-19 | Pliva Research & Development Limited | Pharmaceutical composition of zolpidem |
| CN103641823A (zh) | 2007-04-30 | 2014-03-19 | Abbvie公司 | 二酰甘油o-酰基转移酶1型酶的抑制剂 |
| US8283331B2 (en) * | 2007-10-09 | 2012-10-09 | Children's Medical Center Corporation | Methods to regulate miRNA processing by targeting Lin-28 |
| JP2012522058A (ja) * | 2009-03-31 | 2012-09-20 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤 |
| MA34097B1 (fr) * | 2010-03-30 | 2013-03-05 | Novartis Ag | Utilisations d'inhibiteurs de dgat1 |
| AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
-
2011
- 2011-10-13 AR ARP110103797A patent/AR083417A1/es unknown
- 2011-10-14 BR BR112013008757-9A patent/BR112013008757A2/pt not_active IP Right Cessation
- 2011-10-14 PL PL11779278T patent/PL2627319T3/pl unknown
- 2011-10-14 RU RU2013121795/15A patent/RU2595866C2/ru active
- 2011-10-14 PE PE2013000837A patent/PE20140375A1/es not_active Application Discontinuation
- 2011-10-14 US US13/825,919 patent/US20130190354A1/en not_active Abandoned
- 2011-10-14 JP JP2013534025A patent/JP6060081B2/ja active Active
- 2011-10-14 PT PT11779278T patent/PT2627319T/pt unknown
- 2011-10-14 SG SG2013021944A patent/SG189078A1/en unknown
- 2011-10-14 HU HUE11779278A patent/HUE043524T2/hu unknown
- 2011-10-14 MA MA35806A patent/MA34599B1/fr unknown
- 2011-10-14 SI SI201131677T patent/SI2627319T1/sl unknown
- 2011-10-14 CN CN201180049179.4A patent/CN103179957B/zh active Active
- 2011-10-14 WO PCT/US2011/056275 patent/WO2012051488A1/en active Application Filing
- 2011-10-14 KR KR1020137009333A patent/KR20130100311A/ko not_active Application Discontinuation
- 2011-10-14 ES ES11779278T patent/ES2712064T3/es active Active
- 2011-10-14 TR TR2019/02435T patent/TR201902435T4/tr unknown
- 2011-10-14 MX MX2013004162A patent/MX2013004162A/es not_active Application Discontinuation
- 2011-10-14 DK DK11779278.8T patent/DK2627319T3/en active
- 2011-10-14 NZ NZ608558A patent/NZ608558A/en not_active IP Right Cessation
- 2011-10-14 EP EP11779278.8A patent/EP2627319B1/en active Active
- 2011-10-14 AU AU2011316003A patent/AU2011316003B2/en not_active Ceased
- 2011-10-14 CA CA2813781A patent/CA2813781C/en active Active
-
2013
- 2013-03-20 ZA ZA2013/02108A patent/ZA201302108B/en unknown
- 2013-03-21 IL IL225434A patent/IL225434A0/en unknown
- 2013-04-11 CO CO13094273A patent/CO6710915A2/es not_active Application Discontinuation
- 2013-04-11 GT GT201300096A patent/GT201300096A/es unknown
- 2013-04-12 CL CL2013001001A patent/CL2013001001A1/es unknown
- 2013-04-12 EC ECSP13012755 patent/ECSP13012755A/es unknown
-
2015
- 2015-07-22 US US14/805,919 patent/US20150320687A1/en not_active Abandoned
-
2016
- 2016-09-12 US US15/262,056 patent/US20160374947A1/en not_active Abandoned
-
2018
- 2018-05-01 US US15/968,104 patent/US10646446B2/en active Active
-
2020
- 2020-03-31 US US16/835,921 patent/US11304907B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL225434A0 (en) | Pharmaceutical preparations containing an inhibitor of dgat1 | |
| ZA201300458B (en) | C-met-modulator pharmaceutical compositions | |
| IL221164A0 (en) | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions | |
| ZA201301766B (en) | Pharmaceutical compositions | |
| GB201008005D0 (en) | Pharmaceutical compounds | |
| ZA201207839B (en) | Pharmaceutical composition comprising a pyrimidineone derivative | |
| ZA201300718B (en) | Pharmaceutical compositions | |
| ZA201207670B (en) | Pharmaceutical compositions | |
| ZA201304633B (en) | A pharmaceutical composition | |
| ZA201303223B (en) | Pharmaceutical compositions | |
| GB201020161D0 (en) | Pharmaceutical compounds | |
| ZA201101850B (en) | Composition having a sirtuin activator | |
| ZA201303177B (en) | Pharmaceutical compositions | |
| EP2560678A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| ZA201201003B (en) | A pharmaceutical composition | |
| ZA201202951B (en) | Pharmaceutical composition containing a phenocarbamate acetylcholinesterase inhibitor | |
| ZA201303732B (en) | Pharmaceutical compositions | |
| GB201002162D0 (en) | Packaging thirty three a | |
| IL223324A0 (en) | Novel pharmaceutical compounds | |
| GB201004308D0 (en) | New inhibitor compounds | |
| GB201008590D0 (en) | Pharmaceutical compositions | |
| GB201020365D0 (en) | Pharmaceutical compounds | |
| GB201020364D0 (en) | Pharmaceutical compounds | |
| GB201020068D0 (en) | Pharmaceutical compounds | |
| GB201013968D0 (en) | Pharmaceutical compounds |